HER2 양성 전이성 유방암 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

HER2-Positive Metastatic Breast Cancer Market Outlook

Thelansis's "HER2-Positive Metastatic Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HER2-Positive Metastatic Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

HER2-Positive Metastatic Breast Cancer Overview

HER2-positive metastatic breast cancer is a highly aggressive molecular subtype driven by amplification of the ERBB2 gene, resulting in overexpression of the human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase. Historically associated with rapid disease progression, high visceral involvement, and a strong propensity for central nervous system (CNS) metastases, the disease course has been significantly transformed by targeted therapies.

Accurate determination of HER2 status via immunohistochemistry (IHC) or in situ hybridization (ISH) is essential for guiding treatment. The modern therapeutic paradigm is based on sequential HER2-targeted therapy, beginning with dual monoclonal antibody blockade using trastuzumab and pertuzumab in combination with chemotherapy.

Upon progression, treatment has evolved with the introduction of next-generation antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), which has demonstrated superior efficacy and largely replaced earlier agents such as T-DM1. In later lines, especially for patients with brain metastases, CNS-penetrant tyrosine kinase inhibitors (e.g., tucatinib) play a critical role in achieving both systemic and intracranial disease control.

Key Highlights

• HER2+ mBC is a highly aggressive but targetable cancer subtype with strong dependence on biomarker-driven therapy
• UK prevalent cases expected to grow from ~12.5K to ~15.9K (~2.4% CAGR)

Market Overview

• UK market projected to grow from ~$180M to ~$340M (~6-7% CAGR)
• Growth driven by next-generation ADCs and targeted therapies, with continued innovation in later-line settings

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Ambrx, Inc.
• Criterium, Inc.
• Jazz Pharmaceuticals
• AstraZeneca
• Affibody
• Beijing Biotech
• Jiangsu HengRui Medicine Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Nanjing Chia-tai Tianqing Pharmaceutical

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)